| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d56e7c0120fc7521219652ac9a375934 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616 |
| filingDate |
2011-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae1baa8042323eddb51abd65da35d086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1dd4b580330d3aae898bc38a18a53d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_390a20e9d8e67a5812e3892e3a55b3c5 |
| publicationDate |
2016-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2581158-T3 |
| titleOfInvention |
A pharmaceutical composition comprising aspirin and bisoprolol |
| abstract |
A pharmaceutical capsule containing only two pharmaceutically active ingredients, the capsule containing: a tablet comprising aspirin as the first pharmaceutically active ingredient; and bisoprolol fumarate with a controlled particle size of 90% <425 μm, as the second pharmaceutically active ingredient, mixed with inert excipients and surrounding the tablet; the capsule containing 50 mg to 125 mg of aspirin and 1.25 mg to 15 mg of bisoprolol fumarate; the aspirin tablet being coated with a barrier layer to prevent the chemical interaction between aspirin and bisoprolol fumarate and to prevent the interaction between aspirin and moisture in the capsule; and the aspirin being releasable from the capsule in biological fluids to provide a concentration peak before a bisoprolol concentration peak. |
| priorityDate |
2010-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |